At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
MEDI4736 (anti-PD-L1)drug
Likely dose
MEDI4736 (anti-PD-L1) 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
In Brief
A Phase 2 clinical trial evaluating MEDI4736 (anti-PD-L1) for NSCLC Non-small Cell Lung Cancer. Completed, enrolled 68 participants across 19 sites.
Detailed Summary
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary resectable stage IIIA(N2) NSCLC is efficacious and feasible.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC Non-small Cell Lung Cancer
CountriesSwitzerland
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJun 2016
Primary CompletionJan 2020
Study CompletionMar 2024
TodayJul 2026
First PostedOct 9, 2015
Enrollment StartJun 16, 2016
Primary CompletionJan 20, 2020
Study CompletionMar 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.7 years ago
Interventions
MEDI4736 (anti-PD-L1)drug
fixed dosing 750 mg